News
Lilly’s tirzepatide achieves superior A1C reductions versus insulin glargine
Eli Lilly’s investigational candidate tirzepatide achieved superior A1C and body weight reductions compared with insulin glargine in adults with type 2 diabetes who have increased cardiovascular risk.